Crispr Added to Portfolio

Crispr Therapeutics stock has been added to the portfolio. We paid $39.00 per share. The downturn in the market allowed for the shares to be in our buy zone. There is no plan to sell the shares as of now.

The company's focus is on developing transformative gene-based medicines for serious diseases. KDK Fund believes that there is still an immense amount of value to be mined from this type of research. Crspr Therapeutics is at the leading edge of this research. They have a wonderful, talented team. They have wonderful partnerships. They are in a business that is in its infancy.

The portfolio looks for investments into companies and projects that are having a positive effect on humanity's existence by expanding or creating.


 **All posts on this blog are information and opinions only. They are not to be considered recommendations to buy or sell any security. Please do your due diligence first before trading and investing. Please direct all questions and comments to the blog, kdkfund@gmail.com, or on twitter @kdkfund.